An interventional study of Adrenalectomy in Hypertension, Primary Aldosteronism and Genetic Predisposition to Disease, sponsored by Linkoeping University. Enrolling by invitation at 1 site in Sweden. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by Linkoeping University · Not applicable, Interventional, and Screening
Primary aldosteronism (PA) is a known but underdiagnosed cause of high blood pressure. It is estimated that more than 10% of all people with high blood pressure (HT) suffer from PA, which is often caused by aldosterone-producing adrenal cortical tumors (APAs).
In a pilot study with 35 patients with APAs leading to hypertension, the investigators have identified a genetic variant in a presumed Calcium-channel gene. The variant was significantly overrepresented in patients with APAs compared to the normal population (12% compared to approximately 4%). Interestingly, all patients having APAs and the variant were men.
The SCAPIS study is a world-unique Swedish research study in the field of heart/lungs, in which 30,000 randomly selected people between the ages of 50-64 participated. The study is a collaboration between the universities of Gothenburg, Lund, Linköping, Uppsala and Umeå, as well as the Karolinska Institute in Stockholm. In Linköping, about 5,000 persons participated.
The investigators have now screened 4762 persons from the SCAPIS study for this variant and found it in little less than 6%. Overall, patients with the variant had more often been diagnosed with HT and were mote often treated for HT as well. Interestingly, this difference was only found in men.
The investigators now want to investigate the following:
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's planned enrollment of 76 is below the median of 100 across 4,575 interventional studies indexed under Hypertension.
Browse Hypertension studies →Linkoeping University is the lead sponsor of 193 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Unilateral adrenalectomy is offered
Procedure: Adrenalectomy
Medical treatment is offered
Surgical removal of patients with unilateral primary aldosteronism in patients selected by the presence of a genetic variant and hypertension
Normal aldosterone-renin-ratio
Time frame: 6 months following surgery
Blood pressure both systolic and diastolic
Time frame: 6 months after surgery
Number of antihypertensive drugs
Time frame: 6 months following surgery
Normal potassium level
Time frame: 6 months postoperatively
Plan to share: Yes — all IPD that underlie results in a publication
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.